T. Rowe Price Investment Management, Inc. Krystal Biotech, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 185,550 shares of KRYS stock, worth $28.2 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
185,550Holding current value
$28.2 Million% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding KRYS
# of Institutions
330Shares Held
24.2MCall Options Held
299KPut Options Held
97.6K-
Black Rock Inc. New York, NY3.95MShares$600 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.83MShares$429 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.73MShares$415 Million7.97% of portfolio
-
State Street Corp Boston, MA1.23MShares$186 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA954KShares$145 Million0.03% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.9B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...